SecBot SecBot
8-K ·Filed May 5, 2026

IRON

Disc Medicine, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0001193125-26-205187
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock will trade on pipeline milestones, not quarterly financials. Key catalysts: bitopertin APOLLO topline data (Q4 2026), DISC-0974 ASCO presentation (June 2026), and DISC-3405 data (Q4 2026). Monitor for FDA Type A meeting outcome in Q2 2026.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

Disc Medicine reported Q1 2026 results with a net loss of $63.5M ($1.65/share), wider than the $34.1M loss in Q1 2025, driven by increased R&D and SG&A spending. The company completed enrollment in the Phase 3 APOLLO study for bitopertin (topline data expected Q4 2026) and maintains a strong cash position of $730M, funding operations into 2029. The wider loss and lack of revenue are consistent with a clinical-stage biotech, but the stock will move on pipeline catalysts, not the financials.

Key Financial Metrics

EPS
−$1.65
est −$1.55 · -6.5%
Rating
in line

Key Facts

  • Net loss of $63.5M for Q1 2026 vs $34.1M in Q1 2025
  • Net loss per share of $1.65 vs $1.02 in Q1 2025
  • Cash, cash equivalents, and marketable securities of $730.2M as of March 31, 2026
  • Completed enrollment of Phase 3 APOLLO study for bitopertin in EPP; topline data expected Q4 2026
  • Type A meeting with FDA scheduled for Q2 2026 to review bitopertin resubmission approach
  • Updated Phase 2 data for DISC-0974 in MF anemia selected for oral presentation at ASCO in June 2026
  • Phase 2 study of DISC-3405 in PV and Phase 1b study in SCD progressing; data expected Q4 2026

Financial Impact

Net loss widened by $29.4M YoY to $63.5M; cash burn of ~$61M in Q1 2026

net_losscash_positionr_and_d_expensessga_expenses

Risk Factors

  • Bitopertin received a Complete Response Letter (CRL) from FDA in Feb 2026; approval path uncertain
  • Widening net loss and increasing cash burn rate
  • Clinical-stage biotech with no approved products or revenue
  • Dilution risk from potential future equity offerings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-205187
Document: iron-20260505.htm0001193125-26-205187
Document: 0001193125-26-205187-index-headers.html0001193125-26-205187
Document: 0001193125-26-205187-index.html0001193125-26-205187
Document: 0001193125-26-205187.txt0001193125-26-205187
8-K Data (Synthetic)0001193125-26-205187

Track record

43 reports on IRON

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
  2. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
  3. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  4. Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
  5. Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
  6. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
  7. Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
  8. Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
  9. Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
  10. Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
Showing 10 of 43

US Market Status

Market Closed · Opens in 9h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026